Open | - |
Close | - |
Volume / Avg. | 0 / 725.642K |
Day Range | - - - |
52 Wk Range | 1.795 - 4.705 |
Market Cap | $358.940M |
P/E Ratio | 68.750 |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 35 |
Short Interest | 24.52% |
Days to Cover | 14.53 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Organogenesis Hldgs (NASDAQ: ORGO) through any online brokerage.
Other companies in Organogenesis Hldgs’s space includes: Adverum Biotechnologies (NASDAQ:ADVM), Precigen (NASDAQ:PGEN), Inozyme Pharma (NASDAQ:INZY), Adaptimmune Therapeutics (NASDAQ:ADAP) and Anika Therapeutics (NASDAQ:ANIK).
The latest price target for Organogenesis Hldgs (NASDAQ: ORGO) was reported by Cantor Fitzgerald on Friday, March 1, 2024. The analyst firm set a price target for 5.00 expecting ORGO to rise to within 12 months (a possible 83.82% upside). 8 analyst firms have reported ratings in the last year.
The stock price for Organogenesis Hldgs (NASDAQ: ORGO) is $2.72 last updated March 18, 2024 at 4:40 PM EDT.
There are no upcoming dividends for Organogenesis Hldgs.
Organogenesis Hldgs’s Q1 earnings are confirmed for Wednesday, May 8, 2024.
There is no upcoming split for Organogenesis Hldgs.
Organogenesis Hldgs is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.